Gregory Finn Selected Research

Lung Neoplasms (Lung Cancer)

1/2017

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregory Finn Research Topics

Disease

2	Neoplasms (Cancer) 01/2017 - 06/2004
1	Carcinogenesis 01/2017
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Lung Neoplasms (Lung Cancer) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017
1	Disease Progression 01/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2003

Drug/Important Bio-Agent (IBA)

2	Proteins (Proteins, Gene)FDA Link 01/2017 - 11/2003
1	histidine-rich proteinsIBA 01/2017
1	Hormones (Hormone)IBA 01/2017
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2017
1	PlatinumIBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	seribantumabIBA 01/2017
1	MetalsIBA 06/2004
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 06/2004
1	Phosphotransferases (Kinase)IBA 11/2003
1	Mitogen-Activated Protein KinasesIBA 11/2003
1	Protein Kinases (Protein Kinase)IBA 11/2003
1	MitogensIBA 11/2003
1	6-nitro-7-hydroxycoumarinIBA 11/2003
1	Antineoplastic Agents (Antineoplastics)IBA 11/2003
1	coumarinIBA 11/2003
1	p38 Mitogen-Activated Protein KinasesIBA 11/2003

Therapy/Procedure

1	Therapeutics 01/2017